According to the Zhitong Finance App, BeiGene released its 2023 annual report. During the reporting period, the company achieved operating income of 17.423 billion yuan, a year-on-year increase of 82.13%; net loss attributable to shareholders of listed companies narrowed sharply to 6.716 billion yuan.
Baiyueze, a BTK inhibitor independently developed by the company, has been approved for multiple indications in 70 markets including the United States, China, the European Union, the United Kingdom, Canada, Australia, South Korea and Switzerland. It has established an extensive clinical development layout around the world, and has enrolled more than 5,000 subjects in 29 countries and regions. The final progression-free survival (PFS) analysis results of Baiyueze's “head-to-head” versus ibutinib (Ibutinib) global clinical phase III ALPINE trial for adult patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) were presented as a summary of the latest breakthroughs at the 2022 American Society of Hematology Annual Meeting (ASH) and also published in the “New England Journal of Medicine”.
Baizean has obtained approval for second-line treatment of adult patients with esophageal squamous cell carcinoma (ESCC) in the US, the European Union, and has been approved in the EU for the three first-line and single-agent indications for second-line treatment of metastatic non-small cell lung cancer (NSCLC), accelerating the global registration strategy for this cornerstone therapy. Baizean has been approved for 12 indications in China, 11 of which have been included in the national health insurance catalogue, and its extensive global clinical layout includes more than 13,000 enrolled subjects in more than 30 countries and regions. The company has regained the global rights to develop, produce and commercialize Baizean, strengthening the company's global product portfolio in the field of solid oncology. The company continues to expand Baizean's global footprint and is currently being reviewed by regulators in many overseas countries and regions.